One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood.v130.suppl_1.888.888
Copy DOI Journal: Blood |  Publication Date: Dec 7, 2017 |
 Citations: 10 |
Affiliation: Moffitt Cancer Center, University of Chicago, The University of Texas MD Anderson Cancer Center, Vanderbilt University, Texas Oncology, Baylor University Medical Center, University of California, Los Angeles, University Hospital Würzburg, University of Amsterdam, University of Rennes, Inserm, Centre Hospitalier Universitaire de Rennes, Hôpital Saint-Louis, Kite (United States)Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
